Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Issues Related to the Updated 2014 Korean Guidelines for Tuberculosis

  • Park, Jae Seuk (Department of Internal Medicine, Dankook University College of Medicine)
  • Received : 2015.10.31
  • Accepted : 2015.11.10
  • Published : 2016.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Tuberculosis (TB) remains a major public health problem in South Korea. The Joint Committee for the Development of Korean Guidelines for Tuberculosis published the Korean Guidelines for Tuberculosis in 2011 to provide evidence-based practical recommendations to health care workers caring for patients with TB in South Korea. After reviewing recent national and international scientific data on TB, the committee updated the Korean guidelines for TB in 2014. This article presents some practical issues related to the 2014 updated guidelines: namely use of the Mycobacterium tuberculosis-polymerase chain reaction assay and the Xpert MTB/RIF assay in the diagnosis of TB, as well as medical treatment for patients with multidrug-resistant TB.

Keywords

References

  1. Kim JH, Yim JJ. Achievements in and challenges of tuberculosis control in South Korea. Emerg Infect Dis 2015;21:1913-20. https://doi.org/10.3201/eid2111.141894
  2. Joint Committee for the Development of Korean Guidelines for Tuberculosis; Korea Centers for Disease Control and Prevention. Korean guidelines for tuberculosis. 1st ed. Seoul and Cheongwon: Joint Committee for the Development of Korean Guidelines for Tuberculosis, Korea Centers for Disease Control and Prevention; 2011.
  3. Joint Committee for the Revision of Korean Guidelines for Tuberculosis; Korea Centers for Disease Control and Prevention. Korean guidelines for tuberculosis. 2nd ed. Seoul and Cheongwon: Joint Committee for the Revision of Korean Guidelines for Tuberculosis, Korea Centers for Disease Control and Prevention; 2014.
  4. Singh A, Kashyap VK. Specific and rapid detection of Mycobacterium tuberculosis complex in clinical samples by polymerase chain reaction. Interdiscip Perspect Infect Dis 2012; 2012:654694.
  5. Koh WJ, Chang B, Jeong BH, Jeon K, Kim SY, Lee NY, et al. Increasing recovery of nontuberculous mycobacteria from respiratory specimens over a 10-year period in a tertiary referral hospital in South Korea. Tuberc Respir Dis 2013;75:199-204. https://doi.org/10.4046/trd.2013.75.5.199
  6. Dinnes J, Deeks J, Kunst H, Gibson A, Cummins E, Waugh N, et al. A systematic review of rapid diagnostic tests for the detection of tuberculosis infection. Health Technol Assess 2007; 11:1-196.
  7. Gupta RK, Lawn SD, Booth H, Morris-Jones S. What is the role for Xpert(R) MTB/RIF in high-resource settings? Experience from a central London hospital. Int J Tuberc Lung Dis 2014; 18:1323-6. https://doi.org/10.5588/ijtld.14.0259
  8. Sohn H, Aero AD, Menzies D, Behr M, Schwartzman K, Alvarez GG, et al. Xpert MTB/RIF testing in a low tuberculosis incidence, high-resource setting: limitations in accuracy and clinical impact. Clin Infect Dis 2014;58:970-6. https://doi.org/10.1093/cid/ciu022
  9. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010;363:1005-15. https://doi.org/10.1056/NEJMoa0907847
  10. Barnes PF, Bloch AB, Davidson PT, Snider DE Jr. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1991;324:1644-50. https://doi.org/10.1056/NEJM199106063242307
  11. Lawn SD, Mwaba P, Bates M, Piatek A, Alexander H, Marais BJ, et al. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis 2013;13:349-61. https://doi.org/10.1016/S1473-3099(13)70008-2
  12. Somoskovi A, Parsons LM, Salfinger M. The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis . Respir Res 2001;2:164-8. https://doi.org/10.1186/rr54
  13. Weyer K, Mirzayev F, Migliori GB, Van Gemert W, D'Ambrosio L, Zignol M, et al. Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. Eur Respir J 2013;42:252-71. https://doi.org/10.1183/09031936.00157212
  14. Park YS, Hong SJ, Boo YK, Hwang ES, Kim HJ, Cho SH, et al. The national status of tuberculosis using nationwide medical records survey of patients with tuberculosis in Korea. Tuberc Respir Dis 2012;73:48-55. https://doi.org/10.4046/trd.2012.73.1.48
  15. Millman AJ, Dowdy DW, Miller CR, Brownell R, Metcalfe JZ, Cattamanchi A, et al. Rapid molecular testing for TB to guide respiratory isolation in the U.S.: a cost-benefit analysis. PLoS One 2013;8:e79669. https://doi.org/10.1371/journal.pone.0079669
  16. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, et al. Treatment outcomes among patients with multidrug- resistant tuberculosis: systematic review and metaanalysis. Lancet Infect Dis 2009;9:153-61. https://doi.org/10.1016/S1473-3099(09)70041-6
  17. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis, 2011 update. Geneva: World Health Organization; 2011.
  18. World Health Organization. Policy guidance on drug susceptibility testing (DST) of second-line anti-tuberculosis drugs. Geneva: World Health Organization; 2008.
  19. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012;9: e1001300. https://doi.org/10.1371/journal.pmed.1001300
  20. Chang KC, Yew WW, Tam CM, Leung CC. WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis. Antimicrob Agents Chemother 2013;57:4097-104. https://doi.org/10.1128/AAC.00120-13

Cited by

  1. A Severe Hepatotoxicity by Antituberculosis Drug, and its Recovery in Oriental Hospital vol.37, pp.2, 2016, https://doi.org/10.13048/jkm.16028
  2. WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update: Applicability in South Korea vol.80, pp.4, 2016, https://doi.org/10.4046/trd.2017.0049
  3. Frequency and Type of Disputed rpoB Mutations in Mycobacterium tuberculosis Isolates from South Korea vol.80, pp.3, 2016, https://doi.org/10.4046/trd.2017.80.3.270
  4. Patterns of rpoC Mutations in Drug-Resistant Mycobacterium tuberculosis Isolated from Patients in South Korea vol.81, pp.3, 2016, https://doi.org/10.4046/trd.2017.0042
  5. Machine learning and structural analysis of Mycobacterium tuberculosis pan-genome identifies genetic signatures of antibiotic resistance vol.9, pp.1, 2016, https://doi.org/10.1038/s41467-018-06634-y